A Phase I Randomized Dose/Formulation Comparison Study of SC-52151

NCT00000806 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Telinavir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)